S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Stryker (SYK) Stock Forecast & Price Target

$325.43
-2.02 (-0.62%)
(As of 04/19/2024 ET)

Stryker Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$340.45
4.62% Upside
High Forecast$406.00
Average Forecast$340.45
Low Forecast$292.00
TypeCurrent Forecast
4/22/23 to 4/21/24
1 Month Ago
3/23/23 to 3/22/24
3 Months Ago
1/22/23 to 1/22/24
1 Year Ago
4/22/22 to 4/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$340.45$331.52$319.45$283.89
Predicted Upside4.62% Upside7.29% Upside11.53% Upside7.66% Upside
Get Stryker Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.

SYK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stryker Stock vs. The Competition

TypeStrykerMedical CompaniesS&P 500
Consensus Rating Score
2.77
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside4.62% Upside1,022.47% Upside11.96% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$360.00 ➝ $386.00+13.92%
4/11/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$365.00 ➝ $400.00+15.82%
4/4/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$340.00 ➝ $370.00+4.99%
4/3/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$362.00 ➝ $406.00+15.19%
1/31/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$330.00 ➝ $345.00+2.05%
1/31/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$345.00 ➝ $348.00+3.48%
1/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$336.00 ➝ $364.00+7.94%
1/31/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$360.00+6.66%
12/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$300.00 ➝ $320.00+7.46%
11/9/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$289.00 ➝ $297.00+9.53%
9/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$310.00 ➝ $315.00+10.74%
8/7/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$321.00 ➝ $335.00+16.34%
7/17/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$313.00 ➝ $331.00+9.45%
5/25/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $310.00+13.74%
5/2/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$260.00 ➝ $292.00-0.78%
5/2/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$280.00 ➝ $330.00+10.04%
5/2/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $315.00+5.04%
5/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$320.00 ➝ $345.00+15.04%
5/2/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$280.00 ➝ $310.00+3.37%
5/2/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$287.00 ➝ $315.00+5.04%
4/23/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$275.00 ➝ $336.00+10.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:11 PM ET.

SYK Price Target - Frequently Asked Questions

What is Stryker's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Stryker stock is Moderate Buy based on the current 3 hold ratings and 10 buy ratings for SYK. The average twelve-month price prediction for Stryker is $340.45 with a high price target of $406.00 and a low price target of $292.00. Learn more on SYK's analyst rating history.

Do Wall Street analysts like Stryker more than its competitors?

Analysts like Stryker more than other Medical companies. The consensus rating score for Stryker is 2.77 while the average consensus rating score for medical companies is 2.68. Learn more on how SYK compares to other companies.

Is Stryker being upgraded by Wall Street analysts?

Over the previous 90 days, Stryker's stock had 2 upgrades by analysts.

Does Stryker's stock price have much upside?

According to analysts, Stryker's stock has a predicted upside of 7.69% based on their 12-month stock forecasts.

What analysts cover Stryker?

Stock Ratings Reports and Tools

This page (NYSE:SYK) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners